Immunobiological medicines in treatment of bronchial asthma: experience and prospects of application

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Full Text

Restricted Access

About the authors

N I Ilyina

Institute of Immunology

O M Kurbacheva

Institute of Immunology

L P Sizyakina

Rostov State Medical university of the Russian Ministry of Health

O P Ukhanova

Institute of Postdegree Education of the Stavropol State Medical University

M S Shogenova

Center of Allergology of Public Health Ministry of KBR

V Yu Brisin

Children's Regional Clinical Hospital of Krasnodar Krai


  1. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Op timal Asthma Control study. Am. J. Respir. Crit. Care Med. 2004, v. 170, р. 836-844.
  2. Partridge M.R., van der Molen T., Myrseth S.E., Busse W.W. Attitudes and actions ofasthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm. Med. 2006, v. 6, р. 13.
  3. Novelli F., Latorre M., Vergura L. et al. Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. Pulmonary Pharmacology & Therapeutics. 2015, v. 31, р. 123-129.
  4. Roth M., Zhong J., Zumkeller S. et al. The Role of IgE-Receptors in IgE-Dependent Airway Smooth Muscle Cell Remodelling. PLoS One. 2013, v. 8, e56015.
  5. Burrows B., Martinez F.D., Halonen M. et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N. Engl. J. Med. 1989, v. 320, р. 271-277.
  6. Zureik M., Neukirch C., Leynaert B. et al. Sensitization to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ. 2002, v. 325, р. 411.
  7. Mouthuy J., Detry B., Sohy C. et al. Presence in sputum of functional dust mite-specific IgE antibodies in intrinsic asthma. Am. J. Respir. Crit. Care Med. 2011, v. 184, р. 206-214.
  8. Busse W.W., Morgan W.J., Gergen P.J. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med. 2011, v. 364, р. 1005-1015.
  9. James L., Wenzel S. Clinical relevance of airway remodeling in airway diseases. Eur. Respir. J. 2007, v. 30, р. 134-155.
  10. Wenzel S.E., Schwartz L.B., Langmack E.L. et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 1999, v. 160, р. 1001-1008.
  11. Rabe K.F., Calhoun W.J., Smith N., Jimenez P. Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy. 2011, v. 66, р. 1142-1151.
  12. Hoshino M., Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012, v. 83, р. 520-528.
  13. Roth M., Zhong J., Zumkeller S. et al. The Role of IgE-Receptors in IgE-Dependent Airway Smooth Muscle Cell Remodelling. PLoS One. 2013, v. 8, e56015.
  14. Nopp A., Johansson S.G.O., Adedoyin J. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010, v. 65, р. 56-60.
  15. Wang C., Zhang L. Specific immunotherapy for allergic rhinitis in children. Curr. Opin. Otolaryngol. Head. Neck. Surg. 2014, v. 22, р. 487-494.



Abstract - 10

PDF (Russian) - 1


Article Metrics

Metrics Loading ...


Copyright (c) 2015 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies